Altair Therapeutics Announces Commencement Of A Multi-Center Phase IIa Clinical Trial Of Inhaled AIR645 To Treat Asthma

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial.

View original here: 
Altair Therapeutics Announces Commencement Of A Multi-Center Phase IIa Clinical Trial Of Inhaled AIR645 To Treat Asthma

Related posts:

1. Lorus Therapeutics Announces Positive Result In Its Phase II Clinical Study Of LOR-2040 In Acute Myeloid Leukemia (AML) Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced that its...
2. Santarus Announces Completion Of Enrollment In European Phase III Clinical Trial For Budesonide MMX Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that its collaboration partner, Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA (SIX: COPN), has completed enrollment of 514...
3. Stem Cell Therapeutics Corp. Announces Positive Review By Data Safety And Monitoring Board For The Phase IIb Stroke Trial Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that a regularly scheduled safety analysis has...
4. CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 In Patients With Advanced Soft Tissue Sarcomas CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate a multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a treatment for patients with advanced...
5. Hyperion Therapeutics Enrolls First Patient In Phase II Hepatic Encephalopathy Trial Hyperion Therapeutics, Inc. announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The multi-center study consists of an open...
6. Soligenix Announces Initiation Of A Phase 1/2 Clinical Trial Of SGX201 For The Prevention Of Acute Radiation Enteritis Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced that it has initiated a Phase 1/2 clinical trial...
7. Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial Of Lead IAP Inhibitor HGS1029 In Advanced Lymphoid Tumors Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its...
8. Successful Phase I/II Clinical Trial For BiondVax Pharmaceuticals’ Universal Flu Vaccine BiondVax Pharmaceuticals Ltd. (TASE: BNDK), an Israeli biopharmaceutical company at the forefront of the development of a Universal Influenza Vaccine, announced the success of the Phase I/II clinical trial of...
9. Adeona Announces Publication Of Results Of 160 Patient Phase 2 Clinical Trial Of Oral DnaJP1 For Rheumatoid Arthritis Adeona Pharmaceuticals, Inc. (AMEX: AEN) announced the publication in the journal Arthritis & Rheumatism of results of a 160-patient, six-month, double-blind, placebo-controlled Phase 2 clinical trial using the company's oral...
10. Algeta Announces First US Patient Randomized In ALSYMPCA Phase III Study At Tulane Cancer Center, New Orleans Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase...
11. Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational...
12. Esperion Therapeutics Initiates Phase I Clinical Study For ETC-1002 Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced that the company has initiated a Phase I clinical study...
13. Azaya Therapeutics Receives FDA Authorization To Start Phase I Cancer Trial Azaya Therapeutics, Inc. announced that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product "ATI-1123," a novel and improved formulation of...
14. Lundbeck Starts Clinical Phase IIa With Lu AA24493 (cEPO) In Friedreich’s Ataxia In A Study Also Assessing Efficacy Via Biomarkers H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and tolerability...
15. Lytix Biopharma AS Announces Regulatory Approval By Norwegian And Swedish Authorities To Commence Phase I Clinical Trial Of OncoporeTM In Cancer The Norwegian pharmaceutical company Lytix Biopharma AS announced approvals from the Norwegian Medicines Agency ("Statens legemiddelverk") and the Swedish Medical Products Agency ("Läkemedelverket") to commence Phase I clinical trials of...

« Stopping Tissue Stiffening Is Key To Preventing Aggressive Cancers Federal Lawsuit Filed Over N.J. High School’s Decision To Bar Student From Joining Antiabortion-Rights Protest »